The significance of this perspective is difficult to overstate. KRAS mutations drive a substantial fraction of pancreatic, colorectal, and lung cancers, and for decades the protein was considered undruggable because of its smooth, featureless surface and its extraordinarily tight grip on GTP. Recent years have delivered the first direct inhibitors of mutant KRAS, but their impact has been limited to a specific mutation, G12C, and resistance has emerged rapidly in the clinic. The review’s central thesis is that the next wave of therapeutic opportunity may lie not in the nucleotide pocket itself but in the enzymes that install, read, and remove the chemical tags governing KRAS behavior. By targeting PTM machinery, researchers could in principle control KRAS output even when direct inhibition of the protein fails.

The first and best-characterized layer of this regulation concerns membrane localization. KRAS is a small GTPase that must sit at the inner face of the plasma membrane to encounter its activators and effectors, and its delivery there depends on a sequence of modifications at the carboxyl terminus. A farnesyl or geranylgeranyl lipid group is attached to the CaaX motif, the terminal peptide is cleaved, and the new C-terminus is carboxymethylated. Together these changes anchor the protein in membranes. Additional palmitoylation events, which differ among RAS isoforms, further refine trafficking routes through the Golgi and determine the specific membrane microdomains the protein occupies. The review emphasizes that this spatial organization is not a static address label but a continuously tuned system that shapes signaling output.

What makes this system therapeutically interesting is that every enzymatic step is a potential drug target. The farnesyltransferase inhibitors developed in the 1990s ultimately failed in clinical trials, in part because KRAS was rescued by alternative prenylation through geranylgeranyltransferase. Yet the field has learned from that experience, and the review suggests that modern strategies, including inhibitors of palmitoylation enzymes such as the DHHC acyltransferases and of depalmitoylation machinery, could recalibrate KRAS membrane association with greater precision. Because these enzymes act on the trafficking pathway rather than the nucleotide pocket, they may remain effective even against mutants that evade direct inhibitors.

Beyond localization, the review highlights a second layer of PTM control: the regulation of nucleotide cycling itself. KRAS activity depends on the balance between guanine nucleotide exchange factors, which load GTP, and GTPase-activating proteins, which accelerate hydrolysis back to GDP. Emerging evidence indicates that modifications such as phosphorylation, ubiquitination, and acetylation can tilt this balance by altering the protein’s conformation, its accessibility to regulators, or its interaction surfaces. In this view, the classical GDP/GTP switch is not an autonomous timer but a dial whose sensitivity is continuously adjusted by the cell’s modification state. Understanding how oncogenic mutations interact with these adjustments may explain why tumors with identical KRAS mutations can behave so differently.

A third layer concerns effector engagement. Once KRAS is GTP-bound, it recruits downstream effectors such as RAF kinases, PI3K, and RALGDS to transmit proliferative signals. The review notes that post-translational modifications can modulate the strength and duration of these interactions, effectively deciding which signaling branches dominate in a given cellular context. This has direct clinical relevance: resistance to KRAS inhibitors frequently arises through reactivation of downstream pathways, and if PTMs tune effector coupling, then targeting the modification enzymes could close those escape routes. The authors frame this as a strategy to overcome resistance in KRAS-driven cancers by attacking the regulatory network rather than a single protein-ligand interface.

Protein stability and degradation form a fourth pillar of the review’s argument. Ubiquitination, the attachment of ubiquitin chains, can mark KRAS for destruction by the proteasome, and deubiquitinating enzymes can rescue it. The lifetime of the KRAS protein within the cell is therefore not fixed but actively managed. Small-molecule approaches that exploit this, such as proteolysis-targeting chimeras designed to recruit degradation machinery to KRAS, represent one of the most actively pursued frontiers in the field. The review situates these degrader strategies within the broader PTM framework, arguing that the natural ubiquitination machinery of KRAS provides both a proof of principle and a set of enzymatic handles that degrader drugs could co-opt.

The authors also draw attention to the interplay among different modification types. Phosphorylation, ubiquitination, acetylation, methylation, and lipidation do not operate in isolation; each can influence the others, creating combinatorial codes that specify distinct functional states of the protein. This cross-talk means that inhibiting a single enzyme may produce cascading effects across the network, which is both an opportunity and a caution. The opportunity lies in the potential for lower-dose, network-level interventions that avoid the toxicity of complete KRAS ablation. The caution is that the network’s redundancy may allow cancer cells to compensate, underscoring the need for systematic mapping of modification sites and their functional consequences, which the review identifies as a priority for future research.

Methodologically, the work is a literature review, synthesizing findings from cell biological, structural, and pharmacological studies into a unified framework. The subject of the underlying research is cellular regulation, and the review’s scope spans the full life cycle of the KRAS protein, from its synthesis and membrane delivery to its activation, effector recruitment, and eventual degradation. By organizing this material around the concept of PTM-dependent regulation, the authors offer researchers a conceptual map for designing experiments and, ultimately, combination therapies that pair direct KRAS inhibitors with agents targeting modification enzymes. The review was published in the journal’s 2026 volume under DOI 10.55092/acr20260014.

The broader message for oncology is one of cautious optimism. KRAS-driven cancers remain among the most lethal malignancies, and the initial wave of direct inhibitors, while a historic milestone, has exposed the limits of targeting a single mutation in a single pocket. The PTM perspective reframes the problem: KRAS is not one target but a hub in a regulated network, and every node in that network is a potential point of therapeutic leverage. As the review concludes, targeting PTM enzymes and the modification-dependent regulatory networks they compose may provide new therapeutic opportunities and, critically, strategies to overcome the resistance that has so far blunted the impact of KRAS-directed therapy. For patients with pancreatic, lung, and colorectal cancers, that reframing could not come soon enough.

Subject of Research: Post-translational modifications regulating KRAS protein function and their therapeutic targeting in cancer

Article Title: Post-translational modifications of KRAS: from molecular regulation to therapeutic targeting

Article References: Post-translational modifications of KRAS: from molecular regulation to therapeutic targeting. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: KRAS, post-translational modifications, oncogene, cancer therapy, membrane localization, ubiquitination, palmitoylation, drug resistance, GTPase, signal transduction, protein degradation, Advanced Cancer Research